PATIENTS WITH FOLLICULAR LYMPHOMA (FL) IN MAINTAINED COMPLETE RESPONSE (CR) AT 30 MONTHS SHOW A SURVIVAL SIMILAR TO A SEX‐ AND AGE‐MATCHED SPANISH GENERAL POPULATION

Le résumé fourni par la source

73% of young patients vs 66%, p = 0.0021).The two groups had similar CR24 (32% vs 29%, p = 0.32), CR30 (31% vs 30%, p = 0.57), 5-year estimates for PFS of 44% (95% CI = 41-49 for young patients and 43-46 for patients 40-60) (p = 0.30) and TTP (median TTP 3.9 y vs 4.0 y, HR = 0.96, 95% CI = 0.86-1.08,p = 0.52).OS was significantly higher for young patients with 5-year estimates of 88% (95% CI = 85-90) versus 84% (95% CI = 83-86) (p = 0.003).After adjusting with FLIPI risk group, rituximab use and PS, age <40 was a significant predictor of OS, but not of PFS, TTP or achievement of CR30.Of note, for patients having received rituximab in their first line treatment (n = 1846), patients <40 (n = 265) and patients aged 40-60 (n = 1581) had respective 5-year estimates for PFS of 54% (95% CI = 48-62) and 54% (95% CI = 51-57) (p = 0.70) and for OS of 96% (95% CI = 94-99) versus 90% (95% CI = 88-91) (p = 0.0004) (Figure ).No significant difference in OS was observed between the 2 groups for patients not having received rituximab in first line.These data suggest that among patients treated with rituximab, despite an identical PFS, survival outcomes were statistically higher in the <40 group compared to 40-60.Conclusions: This study reports the clinical characteristics and outcomes in the most important cohort of young patients aged <40 with first-line FL.Age <40 y did not appear to influence the treatment outcome, but was associated with a significantly longer OS.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.